Drugs / MIN-117
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03446846 | Mar 2018 → Nov 2019 | major depressive disorder | Minerva Neurosciences | Completed | Missed primary |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2019-12-18 | Minerva Neurosciences | Results Minerva Neurosciences Reports Topline Results From Phase 2b Trial of MIN-117 in Major Depressive Disorder minervaneurosciences.com ↗
Neither dose of MIN-117 tested in this trial showed a statistically significant separation from placebo on the reduction in the symptoms of MDD over the 6-week treatment period as measured by the change in the Montgomery–Åsberg Depression Rating Scale (MADRS). |
| 2016-09-26 | Minerva Neurosciences | Regulatory Minerva Neurosciences Provides Update on MIN-101 and MIN-117 Clinical Programs minervaneurosciences.com ↗
Company receives FDA acceptance of Investigational New Drug Application for MIN-117 |
| 2016-05-26 | Minerva Neurosciences | Results Minerva Neurosciences Announces Positive Results in Phase IIA Trial of MIN-117 in Major Depressive Disorder minervaneurosciences.com ↗ |
All press releases naming this drug 7 releases
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MIN-117 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03446846 ↗ |
| Route | Oral | “MIN-117 5.0 mg (consisting of two 2.5 mg capsules) orally daily for 6 weeks” NCT03446846 ↗ |